Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence?

IF 2 4区医学 Q3 ONCOLOGY

Oncology Research and Treatment Pub Date : 2023-01-01 DOI:10.1159/000531590

Mohan Hingorani, Hannah Stubley

{"title":"Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence?","authors":"Mohan Hingorani, Hannah Stubley","doi":"10.1159/000531590","DOIUrl":null,"url":null,"abstract":"Background: The concept of oligometastatic disease (OMD) was first introduced in 1995 by Hellman and Weichselbaum and described as stage of transition between localized and widespread metastatic disease. The presence of OMD in esophagogastric (OG) cancer remains controversial. Historically, most experts believe that OG cancer is systemic disease from the outset.Summary: More recently, there is emerging data indicating improved outcomes in patients with OG cancer and oligometastatic disease. The present manuscript focuses on reviewing the emerging evidence in management of metastatic OG cancer with OMD and highlighting the direction of future research.Key messages: Multiple retrospective and at least 2 phase II retrospective studies have reported on improved outcomes in patients with metastatic OG cancer and OMD. There is indication of improved outcome with combined systemic and local therapy (surgery or radiation). Further research should include phase III randomized studies to identify the optimal management algorithm in these groups of patients.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"46 7-8","pages":"312-319"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000531590","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The concept of oligometastatic disease (OMD) was first introduced in 1995 by Hellman and Weichselbaum and described as stage of transition between localized and widespread metastatic disease. The presence of OMD in esophagogastric (OG) cancer remains controversial. Historically, most experts believe that OG cancer is systemic disease from the outset.

Summary: More recently, there is emerging data indicating improved outcomes in patients with OG cancer and oligometastatic disease. The present manuscript focuses on reviewing the emerging evidence in management of metastatic OG cancer with OMD and highlighting the direction of future research.

Key messages: Multiple retrospective and at least 2 phase II retrospective studies have reported on improved outcomes in patients with metastatic OG cancer and OMD. There is indication of improved outcome with combined systemic and local therapy (surgery or radiation). Further research should include phase III randomized studies to identify the optimal management algorithm in these groups of patients.

查看原文本刊更多论文

食管胃癌少转移性疾病的治疗:证据是什么?

背景:寡转移性疾病(OMD)的概念于1995年由Hellman和Weichselbaum首次提出，并将其描述为局部转移性疾病和广泛转移性疾病之间的过渡阶段。食管胃(OG)癌中是否存在OMD仍有争议。从历史上看，大多数专家认为OG癌从一开始就是全身性疾病。摘要:最近，有新的数据表明OG癌和少转移性疾病患者的预后得到改善。本文重点回顾了转移性OG癌合并OMD治疗的新证据，并强调了未来研究的方向。多项回顾性研究和至少2项II期回顾性研究报告了转移性OG癌和OMD患者的预后改善。有迹象表明，全身和局部联合治疗(手术或放疗)改善了结果。进一步的研究应包括III期随机研究，以确定这些患者组的最佳管理算法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Research and Treatment ONCOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.